Adrenal

Top Story

High normal range atrial natriuretic peptide may reduce insulin resistance risk in middle age

February 12, 2016

Exposure during middle age to atrial natriuretic peptide within the high normal range appears to be associated with a reduced risk for insulin resistance after 16.5 years of follow-up.

Amra Jujić, PhD, of the department of cardiology at Skane University Hospital in Sweden, and colleagues evaluated data from the Malmö Diet and Cancer Study cardiovascular cohort on 2,243 patients without diabetes. An immunoluminometric sandwich assay was used to measure midregional pro-atrial natriuretic peptide (MR-proANP). At 16.5 years of follow-up, an oral glucose tolerance test was used to measure glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1, insulin, glucose and glucagon.

In the Journals

Malignancy prevalence higher in primary aldosteronism than hypertension

February 5, 2016
Patients with primary aldosteronism tend to have a higher prevalence of malignancies than patients with hypertension, according to recent study findings. Researchers…
In the Journals

Endogenous cortisol levels associated with lower bone mass in young men

February 3, 2016
Men with high baseline cortisol levels that decrease in response to stress had lower bone mineral content and bone mineral density measurements than men with lower…
In the Journals

Circadian misalignment reduces glucose tolerance in shift workers

January 29, 2016
In shift workers, circadian misalignment appears to cause a decrease in glucose tolerance, independent of behavioral or circadian phase effects, according to recent…
In the Journals

High normal range atrial natriuretic peptide may reduce insulin resistance risk in middle age

February 12, 2016
Exposure during middle age to atrial natriuretic peptide within the high normal range appears to be associated with a reduced risk for insulin…
In the Journals

Malignancy prevalence higher in primary aldosteronism than hypertension

February 5, 2016
Patients with primary aldosteronism tend to have a higher prevalence of malignancies than patients with hypertension, according to recent study…
In the Journals

Endogenous cortisol levels associated with lower bone mass in young men

February 3, 2016
Men with high baseline cortisol levels that decrease in response to stress had lower bone mineral content and bone mineral density measurements than…
In the Journals

Circadian misalignment reduces glucose tolerance in shift workers

January 29, 2016
In shift workers, circadian misalignment appears to cause a decrease in glucose tolerance, independent of behavioral or circadian phase effects…
In the Journals

Salivary cortisone measurements correlate with serum cortisol, offer noninvasive alternative

January 29, 2016
Salivary cortisone measurements strongly correlate with serum cortisol measurements and may serve as a noninvasive alternative to estimate serum…

Beloranib safe, effective in adults with Prader-Willi syndrome

January 24, 2016
Adults with Prader-Willi syndrome randomly assigned the MetAP2 inhibitor beloranib for 6 months saw a significant reduction in both body weight and…
In the Journals

FSH levels may predict bone loss in premenopausal women with breast cancer

January 13, 2016
In premenopausal women with breast cancer treated with chemotherapy, subsequent bone loss may be predicted by higher baseline follicle-stimulating…
In the Journals

Obesity in pseudohypoparathyroidism reduces resting energy expenditure

January 13, 2016
In patients with pseudohypoparathyroidism type 1A, obesity appears to be caused mainly by decreased resting energy expenditure, rather than increased…
In the Journals

Low vitamin D, high parathyroid hormone levels linked in hyperparathyroidism

January 12, 2016
Adults with primary hyperparathyroidism and low vitamin D levels are likely to have high levels of serum parathyroid hormone, indicating more severe…
FDA News

Setmelanotide receives orphan drug designation for treatment of Prader-Willi syndrome

January 8, 2016
The FDA granted orphan drug designation to setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of Prader-Willi syndrome…
More Headlines »
morganatic-roan morganatic-roan